Comprehensive medication guide to Rivastigmine including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10–$30 copay for generic on most commercial plans; Tier 2 on most formularies; Medicare Part D covers with $2,100 annual out-of-pocket cap in 2026.
Estimated Cash Pricing
$18–$50 retail for generic capsules (30-day supply); $163–$424 retail for generic patch; as low as $12–$50 with GoodRx or SingleCare coupons.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Rivastigmine is a prescription medication used to treat dementia associated with Alzheimer's disease and Parkinson's disease. It belongs to the drug class known as cholinesterase inhibitors. The brand name is Exelon — the oral capsule brand has been discontinued, but the Exelon Patch transdermal system remains available alongside multiple generic versions.
Rivastigmine is FDA-approved for mild-to-moderate dementia in Alzheimer's disease and mild-to-moderate dementia associated with Parkinson's disease. The 13.3 mg/24h transdermal patch is additionally approved for severe Alzheimer's dementia. It is the only FDA-approved medication specifically indicated for Parkinson's disease dementia.
Rivastigmine does not cure or reverse these diseases, but it can temporarily improve or stabilize memory, thinking, and the ability to perform daily activities. It is a long-term therapy and must be taken consistently to maintain benefit.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
In Alzheimer's and Parkinson's disease dementia, a key brain chemical called acetylcholine (ACh) is depleted. Acetylcholine is essential for memory, attention, and learning. Rivastigmine works by inhibiting the enzymes — acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) — that break down acetylcholine. By blocking both enzymes, rivastigmine allows acetylcholine to accumulate in brain synapses, improving neuron communication.
Rivastigmine is unique among cholinesterase inhibitors because it inhibits both AChE and BuChE. Competing drugs like donepezil only inhibit AChE. This dual inhibition may offer additional benefit as Alzheimer's disease progresses, since BuChE activity increases in later stages.
The transdermal patch delivers rivastigmine continuously through the skin, avoiding the sharp blood level peaks that cause gastrointestinal side effects with oral capsules. Clinical trials showed the 9.5 mg/24h patch caused one-third fewer nausea and vomiting reports than the highest oral dose, while providing comparable cognitive benefit.
1.5 mg — oral capsule
Starting dose for Alzheimer's dementia (1.5 mg BID)
3 mg — oral capsule
Titration dose — typically after 2 weeks at 1.5 mg
4.5 mg — oral capsule
Titration dose — mid-range oral dose
6 mg — oral capsule
Maximum oral capsule dose (6 mg BID = 12 mg/day)
2 mg/mL — oral solution
Liquid form for patients who cannot swallow capsules
4.6 mg/24h — transdermal patch
Starting patch dose — applied once daily
9.5 mg/24h — transdermal patch
Standard maintenance patch dose
13.3 mg/24h — transdermal patch
Maximum patch dose — approved for all Alzheimer's stages
As of 2026, rivastigmine is not on the FDA's official drug shortage list. Generic rivastigmine capsules, oral solution, and transdermal patches are produced by multiple manufacturers, providing supply resilience. However, patients — especially those needing the transdermal patch — frequently encounter localized stock gaps at individual pharmacies.
The most common availability issues involve specific patch strengths (particularly the 4.6 mg/24h starting dose and 13.3 mg/24h maximum dose), and the transition away from the discontinued brand-name Exelon capsule to generics. Large chain pharmacies and mail-order services generally maintain better inventory than smaller independents.
If you're struggling to find rivastigmine in stock, medfinder calls pharmacies near you to find which ones can fill your prescription — saving you the time and frustration of calling around yourself.
Rivastigmine is not a controlled substance, so any licensed prescriber with appropriate authority can prescribe it. A cognitive assessment (typically the Mini-Mental State Examination) is generally required before initiating therapy to document the stage of dementia and confirm the indication.
Neurologists (most common initiating prescriber for Alzheimer's and Parkinson's disease)
Geriatricians (specialists in elderly patient care)
Geriatric psychiatrists
Movement disorder specialists (for Parkinson's disease dementia)
Primary care physicians (PCPs) — family medicine and internal medicine
Nurse practitioners (NPs) and physician assistants (PAs) with prescribing authority
Telehealth is available for established patients with an existing dementia diagnosis — rivastigmine refills and dose adjustments can often be managed via telehealth visits. New patient evaluations for dementia typically require an in-person cognitive assessment.
No. Rivastigmine is not a controlled substance and has no DEA scheduling. It does not have abuse potential, and there are no federal restrictions on prescription refills, quantity, or prescribing by telehealth based on controlled substance rules.
Rivastigmine can be prescribed by any licensed healthcare provider with prescribing authority — including primary care physicians, neurologists, geriatricians, nurse practitioners, and physician assistants. It can be refilled multiple times on a single prescription and prescribed via telehealth for established patients, subject to state laws.
Nausea (most common — especially during dose titration)
Vomiting
Diarrhea
Loss of appetite and weight loss
Dizziness and headache
Fatigue and weakness
Skin irritation at patch application site (transdermal)
Severe vomiting/diarrhea leading to dehydration
GI bleeding (black/tarry stools, vomiting blood)
Slow or irregular heartbeat, chest pain, fainting
Seizures
Allergic contact dermatitis or Stevens-Johnson syndrome (severe skin reaction)
Cholinergic crisis (overdose: profuse sweating, excessive salivation, bradycardia, seizures — call 911)
Know what you need? Skip the search.
Donepezil (Aricept)
Most commonly prescribed cholinesterase inhibitor; once-daily dosing; FDA-approved for all stages of Alzheimer's; very affordable generic; widely available.
Galantamine (Razadyne)
Dual-mechanism cholinesterase inhibitor (also modulates nicotinic receptors); FDA-approved for mild-to-moderate Alzheimer's; once-daily ER formulation available; not approved for Parkinson's dementia.
Memantine (Namenda)
NMDA receptor antagonist with a different mechanism; FDA-approved for moderate-to-severe Alzheimer's; often combined with a cholinesterase inhibitor for additive benefit; generally well-tolerated with fewer GI side effects.
Namzaric (donepezil + memantine)
Fixed-dose combination of donepezil and memantine extended-release in one once-daily capsule; FDA-approved for moderate-to-severe Alzheimer's; convenient for patients already on both drugs separately.
Prefer Rivastigmine? We can find it.
Anticholinergic drugs (e.g., diphenhydramine, oxybutynin, tricyclic antidepressants)
moderateReduce effectiveness of rivastigmine by blocking acetylcholine receptors — direct pharmacodynamic antagonism.
Bethanechol / other cholinergic agents
moderateAdditive cholinergic effects — increased risk of nausea, vomiting, bradycardia, and other cholinergic side effects.
Metoclopramide (Reglan)
moderateIncreased risk of extrapyramidal symptoms (involuntary movements, tremors). Combination should be avoided, especially in Parkinson's patients.
NSAIDs (ibuprofen, naproxen, aspirin at anti-inflammatory doses)
moderateIncreased gastrointestinal bleeding risk. Rivastigmine increases gastric acid; NSAIDs damage GI mucosa. Use acetaminophen for pain relief if possible.
Succinylcholine-type neuromuscular blockers
majorRivastigmine may prolong neuromuscular blockade during surgery. Inform anesthesiologist before any procedure.
Beta-blockers (metoprolol, atenolol)
minorAdditive bradycardia (slow heart rate). Generally manageable with monitoring but should be disclosed to all treating providers.
Rivastigmine remains one of the most important medications available for managing cognitive symptoms in Alzheimer's and Parkinson's disease dementia. Its dual cholinesterase inhibition, availability in transdermal patch form, and unique FDA approval for Parkinson's dementia make it a valuable and often irreplaceable option for many patients.
While rivastigmine is generally available as a generic, localized pharmacy stock gaps — especially for the transdermal patch — can disrupt treatment. Proactive prescription management, mail-order pharmacy enrollment, and early refill habits are the best defenses against these interruptions.
If you're having trouble finding rivastigmine at a pharmacy near you, medfinder contacts pharmacies on your behalf to find which ones can fill your prescription, and texts you the results. It's the fastest way to locate in-stock rivastigmine without spending time on hold.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini